No Data
Possible Bearish Signals With Taysha Gene Therapies Insiders Disposing Stock
Bank of America Securities Sticks to Its Buy Rating for Taysha Gene Therapies (TSHA)
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $17
Whitney Ijem Reiterates Buy Rating and Maintains $17 Price Target on Clinical Momentum and Strong Cash Runway
Taysha Gene Therapies Reports Q1 EPS (12c), Consensus (10c)
Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $12